Answers are grounded in this paper and cite their sources.
Tumor-associated neutrophil (TAN) enrichment is a defining feature and driving force of brain metastases (BrMs), a leading cause of death in solid tumors. Yet, the mechanisms governing TAN enrichment in BrM remains undefined. Herein, we demonstrate that BrM cell-derived shed soluble mesothelin (sMSLN) critically prolongs neutrophil survival to facilitate tumor cell colonization and outgrowth in the brain. Specifically, sMSLN binds to toll-like receptor 4 (TLR4) on neutrophil to activate the JAK2-STAT3 pathway. This activation promotes lysosomal biogenesis and function, reducing cellular reactive oxygen species (ROS) and inhibiting neutrophil apoptosis. Neutrophil depletion or TLR4-STAT3 blockade abrogates sMSLN-induced BrM progression. Targeting MSLN with Anetumab effectively reduces TAN enrichment, and combining this with TLR4 inhibition synergistically suppresses lung cancer BrM. Our findings establish a critical role for tumor cell-derived sMSLN in sustaining neutrophil longevity and driving BrM, highlighting the sMSLN-TLR4 axis as a promising therapeutic target for brain metastatic tumors.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: